Publication

MHC II on Transfused Murine Blood is Not Required for Alloimmunization Against MHC I

Downloadable Content

Persistent URL
Last modified
  • 02/20/2025
Type of Material
Authors
    Christopher Raleigh Gilson, Emory UniversityChantel M. Cadwell, Emory UniversityNicole H. Smith, Emory UniversityJeanne Hendrickson, Emory UniversityJames C Zimring, Emory University
Language
  • English
Date
  • 2010-11
Publisher
  • Wiley: 12 months
Publication Version
Copyright Statement
  • © 2010 The Author(s). Vox Sanguinis © 2010 International Society of Blood Transfusion
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 0042-9007
Volume
  • 99
Issue
  • 4
Start Page
  • 369
End Page
  • 374
Grant/Funding Information
  • National Heart, Lung, and Blood Institute : NHLBI
  • These studies were supported in part by a grant from the N.I.H. to J.C.Z. (P01 HL086773-project 4)
Abstract
  • Background and Objectives Transfusion of allogeneic platelet products can result in antibodies against donor MHC I antigens, leading to a refractory state to subsequent platelet transfusions. However, there is disagreement in the field regarding the molecular mechanisms of humoral alloimmunization. One hypothesis states that donor MHC II is a requirement for alloimmunization. However, other studies have suggested that donor MHC I is alone sufficient and MHC II is not required. Materials and Methods We utilized a mouse model of anti-MHC I alloimmunization to transfused blood, which employed donors with a complete deletion of all MHC II genes. BALB/c (H-2d) recipients were transfused with blood from either C57BL/6 (H-2b) or MHC II null donors on a C57BL/6 background. Anti-MHC I alloimmunization was monitored by indirect immunofluorescence. Results Recipients of either wild type or MHC II null blood produced equivalent humoral responses against donor MHC I antigens. However, there was variation in the relative amounts of IgG subclasses. Conclusion These data reject the hypothesis that donor MHC II expression is required for alloimmunization to MHC I antigens.
Author Notes
  • To whom all correspondence and requests for reprints should be addressed. Please address correspondence to: James C. Zimring, M.D., Ph.D., Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Woodruff Memorial Building, Suite 7107, 101 Woodruff Circle, Atlanta, GA 30322, USA (Telephone 404-712-2174, Fax 404-727-5764) jzimrin@emory.edu
Keywords
Research Categories
  • Health Sciences, Pathology

Tools

Relations

In Collection:

Items